5 Objectives Only Experts Know About drug Screening Market

 Fingerprint-based drug testing is a relatively new concept. It is non-invasive, less time consuming, portable, hygienic, user-friendly, and requires no specific preparation for sample collection and handling. This test is very easy to implement whenever and wherever it is required, thus offering flexible and effective means of supporting workplace drug testing policies.

The global drug screening market is projected to reach USD 8.63 Billion by 2022 from USD 5.32 Billion in 2017, at a CAGR of 10.2%. Factors such as growing drug & alcohol consumption, enforcement of stringent laws mandating drug and alcohol testing, and regulatory approvals and new product & service launches are driving the growth of the market.

Browse 204 market data Tables and 42 Figures spread through 203 Pages
Download PDF Brochure Now: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=162987773

The objectives of this study are as follows:

1. To define, describe, segment, and forecast the global market by product and service, sample type, end user, and region To provide detailed information regarding the major factors influencing the growth of the market (drivers, restraints, opportunities, challenges, and market-specific trends)
2.To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market
3. To analyze the opportunities in the market for stakeholders and provide details of competitive landscape for market leaders
4. To forecast the size of the market segments with respect to four main regions, namely, North America, Europe, Asia Pacific, and the Rest of the World (RoW). To profile key players and comprehensively analyze their market shares and core competencies
5. To track and analyze competitive developments such as agreements, partnerships, and collaborations; acquisitions; product launches and approvals; expansions; and R&D activities in the global market.

Request Sample Report of drug Screening Market : https://www.marketsandmarkets.com/requestsampleNew.asp?id=162987773

Regional Growth, Development and Demand Analysis:

The market is dominated by North America, followed by Europe, Asia Pacific, and the Rest of the World (RoW). The dominance of the North American market is attributed to factors such as rising consumption of illicit drugs, availability of government funding to curb drug abuse, and the presence of laws supporting drug screening, and growing burden of accidents due to unsafe levels of alcohol consumption.

Alere (US), Thermo Fisher (US), Drägerwerk (Germany), OraSure (US), Alfa Scientific Designs (US), Lifeloc (US), MPD, Inc. (US), Premier Biotech (US), Shimadzu (Japan), Siemens Healthineers (US). While, LabCorp (US), Quest Diagnostics (US), Omega Laboratories (US), Psychemedics (US), CRL (US), SureHire (Canada), and CannAmm (Canada) are some of key players offering drug screening services.

Non Invasive Prenatal Testing (NIPT) Market : Programs Focusing on Increasing the Awareness of NIPT

According to the new market research report "Non-Invasive Prenatal Testing (NIPT) Market by Product (Consumables, Reagent, Ultrasound, NGS, PCR, Microarray), Services, Method (cfDNA, Biochemical Markers), Application (Aneuploidy, Microdeletion) & End-User (Hospital, Labs)-Global Forecasts to 2024 ", published by MarketsandMarkets™, The global non-invasive prenatal testing (NIPT) market is estimated to reach USD 7.3 billion by 2024 from USD 3.9 billion in 2019, at a CAGR of 13.5% during the forecast period.

Growth in this market is driven by the high risk of chromosomal abnormalities with increasing maternal age, growing preference for non-invasive techniques over invasive methods, improving reimbursement scenario for NIPT, and increasing awareness of NIPT. However, a dearth of skilled professionals is restraining the growth of this market.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=145607690

Browse in-depth TOC on “Non-Invasive Prenatal Testing (NIPT) Market ”
112 – Tables
31 – Figures
144 – Pages

The global non-invasive prenatal testing (NIPT) market is estimated to reach USD 7.3 billion by 2024 from USD 3.9 billion in 2019, at a CAGR of 13.5% during the forecast period. Growth in this market is driven by the high risk of chromosomal abnormalities with increasing maternal age, growing preference for non-invasive techniques over invasive methods, improving reimbursement scenario for NIPT, and increasing awareness of NIPT. However, a dearth of skilled professionals is restraining the growth of this market.

Key Questions Addressed by the Report

• Where will all these developments take the industry in the mid to long-term?
• What types of annual and multi-year partnerships are NIPT product and service companies exploring?
• Which are the key players in the market and how intense is the competition?
• Which are the recent contracts and agreements key players have signed?

What are the recent trends affecting NIPT product and service providers?

Key Players in the Global NIPT Market

The NIPT market is diversified and highly competitive, with a large number of players competing for market space. The prominent players in the market are Illumina, Inc. (US), Thermo Fisher Scientific Inc. (US), GE Healthcare (US), BGI (China), Agilent Technologies, Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), PerkinElmer Inc. (US), Laboratory Corporation of America Holdings (US), Natera, Inc. (US), and Yourgene Health (UK)
 

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=145607690

Infectious Disease Diagnostics Market and Increasing Global Prevalence of Infectious Diseases

 Infectious Disease Diagnostics Market by Product & Service (Assay, Kit & Reagent, Instruments), Disease Type (Hepatitis, HIV, HAI, HPV, TB, Influenza), Technology (Immunodiagnostics, PCR, NGS), End User (Hospital, Research Institute) - Global Forecast to 2022

The global infectious disease diagnostics market was valued at USD 13.93 Billion in 2016 and projected to reach USD 19.35 Billion in 2022, at a CAGR of 5.6%.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=116764589

                  

The Infectious Disease Diagnostics Market is Segmented on:

1. Product & Service
2. Disease Type
3. Technology
4. End User

By product and service, assays, kits and reagents segment to record the highest CAGR during the forecast period

Increased accessibility and the increasing number of IDD tests conducted are the key drivers for this segment. Globally, the volume of IDD tests is increasing mainly due to the rising geriatric population; increasing prevalence of infectious diseases; increased variety of reagents available and analytical techniques employed; and the continuous launch of newer, faster, and more reliable products.

By technology, DNA sequencing & next-generation sequencing (NGS) segment to record the highest CAGR during the forecast period

Factors such as advancements in sequencing technologies, increasing awareness and acceptance of personalized medicine (in which this technology has significant applications), and increasing application of molecular diagnostic technologies in pharmacogenetics and point-of-care testing are expected to boost the growth of this technology in the future.

Download PDF Brochure @https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=116764589

Critical questions the report answers:

• Where will all these developments take the industry in the long term?
• What are the upcoming trends for the infectious disease diagnostics market?
• Which segment provides the most opportunity for growth?
• Who are the leading vendors operating in this market?
• What are the opportunities for new market entrants?

Key Market Players

The prominent players in this market areAbbott Laboratories, Becton, Dickinson and Company, Biomérieux SA, Bio-Rad Laboratories, Danaher Corporation, Diasorin, Luminex, Meridian Bioscience, Quidel, Roche Diagnostics, Siemens AG, Thermo Fisher Scientific

Synthetic Biology Market | Wide Range of Applications of Synthetic Biology

The synthetic biology market is projected to reach USD 19.8 billion by 2025 from USD 6.8 billion in 2020, at a CAGR of 23.9%. The growth of this market is primarily attributed to factors such as the increasing demand for synthetic genes & synthetic cells, wide range of applications of synthetic biology, declining cost of DNA sequencing & synthesizing, increasing R&D funding & initiatives in synthetic biology, and increasing investments in the market.

Synthetic Biology Market by Tools (Oligonucleotides, Enzymes, Synthetic Cells), by Technology (Gene Synthesis, Bioinformatics), by Application (Tissue Regeneration, Biofuel, Renewable Energy, Food & Agriculture, Bioremediation) - Global Forecast to 2025

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=889

              
The Synthetic Biology Market is Segmented on:

1. Tools
2. Technology
3. Application

By tool, oligonucleotides and synthetic DNA dominated the synthetic biology market in 2019.
Based on tools, the market segmented into oligonucleotides and synthetic DNA, enzymes, cloning technology kits, synthetic cells, chassis organisms and xeno-nucleic acid. In 2019, the oligonucleotides and synthetic DNA segment accounted for the largest share of the market, followed by enzymes.

Gene synthesis accounted for the largest share of the synthetic biology market in 2019.
Based on technology, the market is segmented into gene synthesis, genome engineering, cloning, sequencing, site-directed mutagenesis, measurement & modeling, microfluidics, nanotechnology, and bioinformatics technologies. In 2019, the gene synthesis segment accounted for the largest share of the market.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=889

Medical applications formed the largest segment of the synthetic biology market in 2019
Based on application, the market is segmented into environmental, medical, industrial, and food & agricultural applications. In 2019, the medical applications segment accounted for the largest share of the market, followed by industrial applications.

The APAC market is expected to grow at the highest CAGR during the forecast period

The market in the Asia Pacific is expected to grow at the highest CAGR during the forecast period. Factors such as growth in the number of pharmaceutical & biopharmaceutical companies, the increasing number of healthcare & life science facilities, and increasing requirements for regulatory compliance in pharmaceutical and biopharmaceutical companies.

Key Players:

The prominent players in the synthetic biology market are Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Agilent Technologies, Inc. (US), Novozymes A/S (Denmark), Ginkgo Bioworks (US), Amyris, Inc. (US), Intrexon Corporation (US), GenScript Biotech Corporation (China), Twist Bioscience (US), Synthetic Genomics, Inc. (US), Codexis, Inc. (US), Synthego Corporation (US)

Autoinjectors Market | Availability of Generic Versions of Autoinjectors

 According to the new market research report “Autoinjectors Market by Therapy (Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Cardiovascular diseases, Psoriasis, Migraine), Type (Disposable, and Reusable), End Users (Homecare, and Hospitals) - Global Forecast to 2023", published by MarketsandMarkets™, The global Autoinjectors Market is projected to reach USD 85.31 billion by 2023 from an estimated USD 28.91 billion in 2018, at a CAGR of 24.2% during the forecast period (2018-2023).

The key factors driving the growth of this market include the growing prevalence of targeted therapies such as rheumatoid arthritis and multiple sclerosis, rising incidence of anaphylaxis, and increasing number of regulatory approvals.

Get Sample Report @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=173991724

                     

The patent expiry of biologics in the coming years is also expected to provide growth opportunities for players in the autoinjectors market

Autoinjectors are used to self-administer drugs for the treatment of various diseases and conditions, such as rheumatoid arthritis, multiple sclerosis, diabetes, and anaphylaxis. Autoinjectors are easy to use, portable, and improve dosing accuracy, making them one of the most popular methods for the self-administration of drugs.

Disposable autoinjectors segment is expected to grow at the highest CAGR during the forecast period.
disposable autoinjectors are the most-preferred autoinjectors due to their ease of use and the presence of a built-in glass syringe (eliminates the need for manually loading the glass syringe), which makes it more convenient for patients with reduced dexterity or visual impairments.

Critical questions the report answers:

⏩ Which are the most significant revenue-generating regions for the market?
⏩ What are the significant upcoming trends in the market?
⏩ How will the market drivers, restraints, and future opportunities affect the market dynamics?
⏩ Which end-user segment is expected to witness maximum growth opportunities during the forecast period?

North America to witness the highest market growth during the forecast period
The large share of the North American autoinjectors market can primarily be attributed to the rising prevalence of autoimmune and chronic diseases, increasing prevalence of anaphylaxis, and the increasing number of FDA approvals in the region.

Download PDF Brochure @https://www.marketsandmarkets.com/requestsampleNew.asp?id=173991724

Bioinformatics Market | Growing Demand for Nucleic Acid and Protein Sequencing

Bioinformatics is the application of computer technology for the management and analysis of biological data. It includes collection, storage, retrieval, manipulation, and modelling of data for analysis, visualization, or prediction through algorithms and software.

The global bioinformatics market is expected to account for USD 7,063.7 billion in 2018. It is expected to reach USD 13,901.5 billion by 2023, at a CAGR of 14.5% during the forecast period. Growth of the bioinformatics market is driven by the growing demand for nucleic acid and protein sequencing, increasing government initiatives and funding, and increasing use of bioinformatics in drug discovery and biomarker development processes.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=39

The Bioinformatics Market is Segmented on:

1. Product & Service
2. Applications
3. Sectors

By Product and Services, bioinformatics platforms segment is expected to be the fastest-growing segment in the forecast period
Knowledge management tools commanded the largest market share in the global bioinformatics market in 2018, while the bioinformatics platforms segment is expected to be the fastest-growing segment in the forecast period. The major factor driving growth of bioinformatics platforms is their growing use in various genomic applications.

By Application, the metabolomics segment is expected to grow at the highest CAGR during the forecast period
Factors such as the availability of research funding and government support are fueling market growth. However, metabolomes cannot be easily identified or figured from reconstructed biochemical pathways due to enzymatic diversity, substrate ambiguity, and difference in regulatory mechanisms.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=39

By Sector, medical biotechnology segment is expected to grow at the highest CAGR during the forecast period
Various pharmaceutical companies are increasingly adopting bioinformatics tools to decrease the cost and time involved in drug discovery.

Bioinformatics approaches for target discovery and validation are proving more efficient than traditional methods. With the help of bioinformatics tools, much of the information regarding drug candidates is validated at a molecular level, which tends to reduce drug attrition rate in the later stages of drug development.

Regional Analysis:

The market in the Asia Pacific region is expected to offer significant opportunities for players to offset revenue losses incurred in mature markets. Emerging countries in this region are witnessing growth in their GDPs and a significant rise in disposable income levels.

Key Players:
Thermo Fisher Scientific, Eurofins Scientific, Illumina, Perkinelmer, Inc., Qiagen Bioinformatics, Agilent Technologies, Dnastar, Waters Corporation, Sophia Genetics, Partek, Biomax Informatics AG, Wuxi Nextcode, Beijing Genomics Institute (BGI).

Gas Chromatography Market worth $3761.0 million by 2022 – Exclusive Report by MarketsandMarkets™

The growth in this market is driven by factors such as increase in crude & shale oil production, increasing importance of waste water treatment, rising adoption of GC-MS, initiatives to reduce environmental pollution levels, growing food safety concerns, and increased importance of chromatography in drug testing.

Access Sample Research Copy : https://www.marketsandmarkets.com/requestsampleNew.asp?id=101656773

The overall gas chromatography market is expected to reach USD 3671.0 million by 2022 from USD 2647.0 million in 2016, at a CAGR of 6.2%. The increasing crude & shale oil production, increasing importance of waste water treatment, rise in adoption of GC-MS, initiatives to reduce environmental pollution levels, growing food safety concerns and increased importance of chromatography tests in drug are the key factors driving the growth of this market. Owing to technological advancements, GC systems are witnessing a shift from laboratory settings to miniaturization, thus increasing their scope in production plants

Moreover, these advancements also increase the capabilities of gas chromatography in the analysis of complex compounds. For instance, the MicroGC Fusion is a small, easy to use, gas chromatograph (GC) specifically designed for gas analysis in the concentration range of low ppm to percentage levels.

                                 
Download PDF Brochure : https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=101656773

Geographical Growth Analysis:

The market in North America is expected to grow at the fastest CAGR during the forecast period. The increase in the U.S. shale gas production, growing funding for Environmental Testing and clean-up in Canada, increasing funding for R&D activities in healthcare & environmental industries, and growth in food testing industries are driving the growth of this region.

What Drives the Market?

1. Increasing Crude & Shale Oil Production
2. Collaborations Between Chromatography Instrument Manufacturers and Research Laboratories/Academic Institutes
3. Increasing Focus on Waste Water Treatment
4. Rising Adoption of Gc-Ms
5 .Development of Policies and Initiatives to Reduce Environmental Pollution Levels
6. Growing Food Safety Concerns
7.Growing Importance of Chromatography Tests in the Drug Approval Process

The prominent players in the Gas chromatography market are Agilent Technologies, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Shimadzu Corporation (Japan), PerkinElmer, Inc. (U.S.), Danaher Corporation (U.S.), Scion Instruments (Techcomp USA Inc.), LECO Corporation (U.S.), Merck KGaA (Germany), Falcon Analytical Systems & Technology, LLC (U.S.), Restek Corporation (U.S.), Dani Instruments S.p.A. (Italy), and Chromatotec (France).

Read More in Detailed (Gas chromatography market): https://www.marketsandmarkets.com/PressReleases/gas-chromatography.asp

Genotyping Assay Market is projected to reach $ 31.9 billion | CAGR of 22.0% by 2023

The increasing incidence of genetic diseases and rising awareness of personalized medicine, growing importance of genotyping in drug development, and the increasing demand for bioinformatics solutions in data analysis are also expected to promote market growth in the coming years.

MarketsandMarkets forecasts the Genotyping Assay market to grow from USD 11.8 billion in 2018 to USD 31.9 billion by 2023, at a Compound Annual Growth Rate (CAGR) of 22.0% during the forecast period.

🔽 The study involved four major activities to estimate the current market size for particle therapy. Exhaustive secondary research was done to collect information on the market and its different subsegments. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size.

🔽 The major factors that are expected to be driving the genotyping assay market are technological advancements and the decreasing prices of DNA sequencing.

Browse 219 market data Tables and 53 Figures spread through 280 Pages
Download PDF Brochure Now:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=249958595

                             
End User of Genotyping assay market:

1. Pharmaceutical and Biopharmaceutical Companies 
2. Diagnostic and Research Laboratories
3. Academic Institutes
4. Other End Users (Animal and Aqua Genetics Companies, Greenhouses, and Farms) 

🔽 The objective of the report is to define, describe, and forecast the genotyping assay market size based on product & service, technology, application, end user, and region.

🔽 By technology, the sequencing segment to record the highest CAGR during the forecast period
The sequencing segment is expected to witness a faster growth rate in this market due to factors such as, the increasing application areas of DNA sequencing technologies, technological advancements, the availability of high-speed sequencing instruments, and the growing uptake of the hybrid approach of sequencing.

🔽 Regional Growth, Development and Demand Analysis:

North America is expected to hold the largest market size in the global genotyping market during the forecast period, followed by the European region. The increasing adoption of technologically advanced genotyping products, the high healthcare expenditure, presence of advanced healthcare infrastructure, highly developed healthcare systems in the US and Canada.

Request Sample Report of Particle Therapy Market: https://www.marketsandmarkets.com/requestsampleNew.asp?id=249958595

🔽 Key Players:

Illumina (US), Thermo Fisher Scientific (US), QIAGEN (Netherlands), Agilent Technologies (US), Danaher Corporation (US), Roche Diagnostics (Switzerland), GE Healthcare (US), Fluidigm Corporation (US), PerkinElmer (US), Eurofins Scientific (Luxembourg), Bio-Rad Laboratories (US), Pacific Biosciences of California (US), GENEWIZ (US), and Integrated DNA Technologies (US).

Illumina is the leading player in the genotyping market. The company led the sequencing market with its flagship NGS platforms—iSeq 100 system (launched in January 2018), NovaSeq 6000, HiSeq Series, MiSeq Series, NextSeq 500, and HiSeq X Ten & HiSeq X Five.

Anatomic Pathology Market | Growing Focus on Personalized Medicine

The anatomic pathology market is estimated to grow from USD 33.0 billion in 2019 to USD 44.4 billion by 2024, at a CAGR of 6.1%. The growth in this market is majorly driven by the high incidence of cancer and other target diseases, availability of reimbursement, and the growing focus on personalized medicine.

However, the availability of refurbished products, the lack of skilled professionals, and product recalls are expected to hamper market growth to a certain extent during the forecast period.

Anatomic Pathology Market by Product & Service (Instruments (Tissue Processing Systems, Microtomes), Consumables (Antibodies), Histopathology), Application (Disease Diagnosis (Cancer (Gastrointestinal)), End User (Hospital, Lab) - Global Forecast to 2024

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=137323145

The Anatomic Pathology Market is Segmented on:

1. Product & Service
2. Consumables
3. Application
4. End User

Services segment to witness the highest growth during the forecast period
By product & service, the market is segmented into services, instruments, and consumables. The services segment accounted for the largest market share in 2018 and is expected to register the highest CAGR during the forecast period.

Disease diagnosis segment accounted for the largest share of the anatomic pathology market, by application, in 2018
Based on application, the market is segmented into disease diagnosis and medical research. The market for disease diagnosis is further segmented into cancer and other diseases. In 2018, the disease diagnosis segment accounted for the largest market share.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=137323145

North America is the largest regional market for anatomic pathology

In 2018, North America accounted for the largest market share, followed by Europe. The easy accessibility to advanced technologies, government initiatives for screening cancer patients, favorable reimbursement scenario for anatomic pathology diagnostic tests, increasing healthcare expenditure, and the presence of high-quality infrastructure for hospitals and clinical laboratories in the region are the major factors driving the growth of the market in North America.

Key Players:

Prominent players in the anatomic pathology market include F. Hoffmann-La Roche Ltd. (Switzerland), Danaher Corporation (US), Thermo Fisher Scientific (US), Hologic, Inc. (US), Agilent Technologies (US), Becton, Dickinson and Company (US), Sakura Finetek (Japan), Merck KGaA (Germany), Bio SB (US), Diapath S.p.A. (Italy), and BioGenex Laboratories (US).

Vaccine Adjuvants Market | High Prevalence of Infectious and Zoonotic Diseases

The global vaccine adjuvants market is expected to reach USD 769.4 Million by 2021 from USD 467.0 Million in 2016, at a CAGR of 10.5%. The global market is broadly classified into product type, route of administration, disease type, applications, and application categories.

Vaccine Adjuvants Market by Product Type (Particulate, Emulsions, Pathogen, Saponin), Route of Administration (Subcutaneous, Intramuscular), Disease Type (Infectious, Cancer), Application (Research, Commercial) & Application Category - Forecasts to 2021

Download PDF Brochure @https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=152603894

                          
The Global tensiometer market is Segmented on:

1. Type
2. Route of Administration
3. Disease Type
4. Application
5. Application Category

On the basis of product type, the vaccine adjuvants market is segmented into pathogen components, adjuvant emulsions, particulate adjuvants, combination adjuvants, and others. The particulate adjuvants segment is expected to account for the largest share of the global market in 2016. The adjuvant emulsions segment, on the other hand, is projected to grow at the highest CAGR during the forecast period.

On the basis of route of administration, the market is segmented into oral, subcutaneous, intranasal, intramuscular, intradermal, and others. The intramuscular segment is expected to account for the largest share of the global vaccine adjuvants market in 2016. Factors such as the rapidly growing geriatric population and vaccines for improved immunization are propelling the growth of this market.

Regional Analysis:

Geographically, the vaccine adjuvants market is dominated by North America, followed by Europe, Asia, and the Rest of the World (RoW). However, Asia is projected to grow at the highest CAGR during the forecast period. Growth in the North American segment is primarily driven by the increasing geriatric population and rising incidences of diseases in the North American countries.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=152603894

Key Players:

Brenntag Biosector (Denmark), CSL Limited (Australia), SEPPIC (France), Agenus, Inc. (U.S.), Novavax, Inc. (U.S.), SPI Pharma, Inc. (U.S.), Invivogen (U.S.), Avanti Polar Lipids, Inc. (U.S.), MVP Laboratories, Inc. (U.S.), and OZ Biosciences (France).

Digital Therapeutic (DTx) Market and the Significant increase in venture capital investments

The global digital therapeutics market is projected to reach USD 6.9 billion by 2025 from USD 2.1 billion in 2020, at a CAGR of 26.7% during the forecast period (2020–2025). The growth of the digital therapeutics market is primarily driven by factors such as government initiatives for preventive healthcare, technological advancements in mobile healthcare, a significant increase in venture capital investments, and the benefits of digital therapeutics, such as the ability to induce behavioral change (an important challenge in healthcare), user-friendliness, patient convenience, and improved drug compliance.

Digital Therapeutic (DTx) Market by Application (Prediabetes, Nutrition, Care, Diabetes, CVD, CNS, CRD, MSD, GI, Substance Abuse, Rehabilitation), Sales Channel (B2C, Patient, Caregiver, B2B, Providers, Payer, Employer, Pharma) - Global forecasts to 2025

Rising healthcare costs, the growing prevalence of chronic diseases, and the ability of digital therapeutics to provide cost-effective solutions are some factors responsible for driving the market for treatment/care-related digital therapeutics applications.

Download PDF Brochure @https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=516467241

              

B2B segment is expected to grow at the highest CAGR during the forecast period

Based on the sales channel, the digital therapeutics market is segmented into business-to-customer (B2C) and business-to-business (B2B). In 2019, the B2B segment accounted for the largest market share; it is also expected to grow at the highest CAGR of the digital therapeutics market.

Caregivers segment is expected to dominate the market

Based on the type of buyer, the B2C sales channel market is further segmented into patients and caregivers. The caregivers segment is expected to dominate the market and register the highest CAGR during the forecast period. The high growth of this segment is attributed to company initiatives for the development of products specifically for caregivers and the fact that digital therapeutics help caregivers in better managing their patients.

Request for Sample Pages @https://www.marketsandmarkets.com/requestsampleNew.asp?id=51646724

North America accounted for the largest share of the digital therapeutics market in 2019.

The global digital therapeutics market is segmented into North America, Europe, the Asia Pacific, and the RoW. In 2019, North America (US and Canada) held the largest share of the market, followed by Europe. The major factors supporting market growth include the increasing investments in digital therapeutics, the influx of new start-ups, improvements in the reimbursement structure for digital therapeutics, and government initiatives to support technological advancements.

Key Market Players

The prominent players in this market are Noom (US), Livongo Health (US), Omada Health (US), WellDoc (US), Pear Therapeutics (US), Proteus Digital Health (US), Propeller Health (US), Akili Interactive Labs (US), Better Therapeutics (US), Happify (US), Kaia Health (Germany), Mango Health (US), Click Therapeutics (US), Canary Health (US), Wellthy Therapeutics (India), Cognoa (US), Ayogo Health (Canada), Mindstrong Health (US), 2Morrow (US), and Ginger (US).

Key Questions Addressed by the Report :

⏩ Where will these developments take the industry in the mid to long-term?
⏩ What types of annual and multi-year partnerships are companies in the digital therapeutics market exploring?
⏩ Who are the key players in the market, and how intense is the competition?
⏩ What are the recent contracts and agreements that key players have signed?
⏩ What are the recent trends affecting digital therapeutics market players?

Get More Information @https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=51646724